Flu vaccine for h1n1. H1N1 Influenza Vaccine: Comprehensive Guide to Prevention and Treatment

02.09.202308.07.2023 by alexxlab

What is H1N1 influenza. How does the H1N1 vaccine work. What are the types of H1N1 vaccines available. Who should get vaccinated against H1N1. How effective is the H1N1 vaccine. What are the potential side effects of the H1N1 vaccine. Where can I get the H1N1 vaccine.

Содержание

Understanding H1N1 Influenza: Origins and Symptoms

H1N1 influenza, initially referred to as swine flu, emerged as a novel strain of influenza virus in 2009. This highly contagious virus rapidly spread across the globe, prompting the World Health Organization to declare a pandemic. But what exactly is H1N1 influenza?

H1N1 is a subtype of influenza A virus that primarily affected pigs before mutating to infect humans. The 2009 strain was particularly concerning due to its ability to spread easily from person to person. Transmission occurs through respiratory droplets when an infected individual coughs, sneezes, or talks, as well as through contact with contaminated surfaces.

The symptoms of H1N1 influenza closely resemble those of seasonal flu:

Fever
Cough
Sore throat
Body aches
Headache
Fatigue
Chills

In some cases, individuals infected with H1N1 may also experience diarrhea and vomiting. The similarity in symptoms between H1N1 and seasonal flu can make diagnosis challenging without specific testing.

The Development and Importance of H1N1 Vaccines

In response to the 2009 pandemic, pharmaceutical companies rapidly developed vaccines specifically targeting the H1N1 strain. These vaccines play a crucial role in preventing the spread of the virus and reducing the severity of infections. How do H1N1 vaccines work?

H1N1 vaccines stimulate the immune system to produce antibodies against the virus. When exposed to the actual virus, these antibodies help the body recognize and fight off the infection more effectively. This process significantly reduces the risk of severe illness, hospitalization, and death associated with H1N1 influenza.

It’s important to note that H1N1 vaccines are distinct from seasonal flu vaccines. While seasonal flu shots protect against multiple strains of influenza, including H1N1, the specific H1N1 vaccine provides targeted protection against this particular strain.

Types of H1N1 Vaccines

Two primary types of H1N1 vaccines are available:

Inactivated Influenza Shot: This vaccine contains killed virus particles and is administered via injection into the muscle. It’s suitable for most individuals, including those with chronic health conditions.
Live Attenuated Intranasal Vaccine (LAIV): This nasal spray contains weakened live viruses. It’s generally recommended for healthy individuals between 2 and 49 years old who are not pregnant.

Both types of vaccines are effective in preventing H1N1 influenza, but the choice between them depends on individual health factors and age.

Who Should Get the H1N1 Vaccine?

While H1N1 vaccination is beneficial for most people, certain groups are at higher risk of complications from the virus and should prioritize getting vaccinated. These groups include:

Pregnant women
Children and young adults aged 6 months to 24 years
Healthcare workers and emergency medical personnel
Adults aged 25-64 with chronic health conditions or weakened immune systems
Caregivers of infants under 6 months old

Is the H1N1 vaccine safe for everyone? While generally safe, some individuals should avoid certain types of H1N1 vaccines. For instance, people with severe egg allergies should consult their healthcare provider before vaccination, as some vaccines are produced using egg-based technology.

Effectiveness and Safety of H1N1 Vaccines

The efficacy of H1N1 vaccines has been a subject of extensive research since their introduction. Studies have shown that these vaccines are highly effective in preventing H1N1 influenza and reducing the severity of symptoms in those who do become infected.

How effective are H1N1 vaccines? Clinical trials have demonstrated that H1N1 vaccines can reduce the risk of infection by 70-90% in healthy adults. Even in cases where vaccinated individuals contract the virus, they typically experience milder symptoms and a lower risk of complications.

Regarding safety, H1N1 vaccines undergo rigorous testing before approval. The most common side effects are mild and include:

Soreness at the injection site
Low-grade fever
Muscle aches
Fatigue

Severe allergic reactions are extremely rare, occurring in less than 1 in a million doses. The benefits of vaccination far outweigh the potential risks for most individuals.

Strategies for Preventing H1N1 Influenza Beyond Vaccination

While vaccination is the most effective method of preventing H1N1 influenza, complementary strategies can further reduce the risk of infection and transmission. These preventive measures include:

Practicing good hand hygiene: Frequent handwashing with soap and water for at least 20 seconds can significantly reduce the spread of the virus.
Using alcohol-based hand sanitizers: When soap and water are unavailable, hand sanitizers with at least 60% alcohol content can be effective.
Avoiding touching the face: The virus can enter the body through the eyes, nose, and mouth, so minimizing face-touching is crucial.
Practicing respiratory etiquette: Covering the mouth and nose when coughing or sneezing, preferably with a tissue or the elbow, helps prevent the spread of respiratory droplets.
Maintaining social distance: Staying at least 3-6 feet away from individuals showing flu-like symptoms can reduce the risk of transmission.
Staying home when sick: Individuals experiencing flu-like symptoms should isolate themselves to prevent spreading the virus to others.

How effective are these preventive measures? When combined with vaccination, these strategies can significantly reduce the overall incidence of H1N1 influenza in communities.

Treatment Options for H1N1 Influenza

Despite prevention efforts, some individuals may still contract H1N1 influenza. In such cases, prompt treatment is essential to manage symptoms and prevent complications. What are the primary treatment options for H1N1 influenza?

Antiviral Medications

Antiviral drugs are the cornerstone of H1N1 treatment. The most commonly prescribed antivirals include:

Oseltamivir (Tamiflu)
Zanamivir (Relenza)
Peramivir (Rapivab)

These medications work by inhibiting the virus’s ability to replicate in the body. They are most effective when started within 48 hours of symptom onset and can reduce the duration and severity of illness.

Supportive Care

In addition to antiviral therapy, supportive care plays a crucial role in managing H1N1 symptoms:

Rest: Adequate rest allows the body to focus energy on fighting the infection.
Hydration: Consuming plenty of fluids helps prevent dehydration, a common complication of influenza.
Over-the-counter pain relievers: Acetaminophen or ibuprofen can help reduce fever and alleviate body aches.
Humidifiers: Using a humidifier can help ease congestion and coughing.

For severe cases or individuals at high risk of complications, hospitalization may be necessary to provide more intensive supportive care, including oxygen therapy or mechanical ventilation.

Global Impact and Future Outlook of H1N1 Influenza

The 2009 H1N1 pandemic had far-reaching consequences, affecting millions worldwide and highlighting the importance of global preparedness for infectious disease outbreaks. How has the landscape of H1N1 influenza changed since the initial pandemic?

Since 2009, H1N1 has become one of the circulating seasonal flu strains, included in annual flu vaccines. This integration into seasonal flu patterns has led to increased population immunity and reduced severity of outbreaks. However, the potential for future H1N1 mutations remains a concern for public health officials.

Ongoing surveillance and research efforts focus on:

Monitoring for new H1N1 variants
Improving vaccine technologies for faster production and broader protection
Developing universal flu vaccines that could protect against multiple strains, including potential pandemic variants
Enhancing global collaboration for early detection and response to emerging influenza threats

These efforts aim to better prepare the world for future influenza pandemics, using lessons learned from the 2009 H1N1 outbreak to inform strategies and policies.

Accessing H1N1 Vaccines and Healthcare Resources

For individuals seeking H1N1 vaccination or treatment, numerous resources are available. Where can one obtain H1N1 vaccines?

Healthcare provider offices
Local pharmacies
Community health centers
Public health departments

Many of these locations offer both seasonal flu vaccines (which include protection against H1N1) and specific H1N1 vaccines when available. It’s advisable to call ahead to confirm vaccine availability and any requirements for vaccination.

For those experiencing flu-like symptoms or seeking more information about H1N1 influenza, the following resources can be helpful:

CDC website (www.cdc.gov): Offers comprehensive information on influenza, including H1N1, prevention strategies, and treatment guidelines.
World Health Organization (www.who.int): Provides global updates on influenza trends and pandemic preparedness.
Local health department websites: Often offer region-specific information on flu activity and vaccination clinics.
Telemedicine services: Many healthcare providers now offer virtual consultations for initial assessment of flu-like symptoms.

By utilizing these resources and staying informed about H1N1 influenza, individuals can take proactive steps to protect their health and contribute to community-wide disease prevention efforts.

h2N1 Influenza (Swine Flu) – APIC

October 18-24, 2009 is International Infection Prevention Week (IIPW). IIPW is an annual event to raise awareness about the importance of infection prevention and what consumers can do to guard against infections. As h2N1 influenza continues to spread and more people become infected with the virus, APIC’s message for IIPW 2009 focuses on how consumers can stay healthy during this flu season.

Background on h2N1
The 2009 h2N1 influenza virus (previously called swine flu) is a new strain of influenza virus. It is very contagious and has spread to many areas of the United States and other countries resulting in a pandemic.

It is believed that the h2N1 flu spreads the same way that seasonal flu does. These viruses are transmitted mainly from person-to-person as a result of exposure to people who have flu like symptoms who are coughing and/or sneezing. People can also become infected by touching something that has flu virus on it and then touching their eyes, nose or mouth.

Symptoms of h2N1 flu are similar to regular seasonal flu and include: fever, cough, sore throat, sneezing, body aches, headaches, chills and fatigue. Some persons have also reported diarrhea and vomiting.

2009 h2N1 Influenza Vaccine
Getting vaccinated is the single best way to protect against influenza illness. h2N1 flu vaccines are now available. They are made the same way and by the same manufacturers as seasonal flu vaccine. This vaccine will not prevent influenza-like illnesses caused by other viruses; therefore, you must get both the seasonal influenza vaccine and the h2N1 influenza vaccine. To find out where to get seasonal or h2N1 vaccines, visit http://www.flu.gov/.

There are two kinds of 2009 h2N1 vaccines available:

2009 h2N1 flu shot (inactivated influenza shot) – This is just like the annual flu shot that is given with a needle; it has killed virus in it and is injected into the muscle. One form of the vaccine contains a preservative called thimerosal; another form is preservative free. For more information, visit the CDC’s website: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-inact-h2n1.pdf
2009 h2N1 nasal spray flu vaccine (Live Attenuated Intranasal Vaccine — LAIV). This is a weakened virus in a vaccine that is sprayed into the nose. Certain groups may not get the nasal spray vaccine: pregnant women, people with certain long-term illnesses such as diabetes, asthma etc., children from 6 months to 2 years old, and adults 50 years or older. If you cannot get the nasal spray flu vaccine, you should get the h2N1 flu shot. For more information, please see: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-laiv-h2n1.pdf and http://www.cdc.gov/h2n1flu/vaccination/nasalspray_qa.htm

The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have identified ways to stay healthy and guard against the flu:

Cough into your sleeve or cover your nose and mouth with a tissue when you cough or sneeze. Throw the tissue in the trash after you use it.
Wash your hands often with soap and water, especially after you cough or sneeze. Alcohol-based hand cleaners are also effective and should be used frequently.
Avoid touching your eyes, nose, or mouth. Germs spread that way.
Avoid close contact with sick people (stay 3-6 feet away).
If you get sick, stay home from work or school and limit contact with others to keep from infecting them.

APIC reminds everyone: Do not visit patients in the hospital or any other healthcare facility if you think you may have the flu.

Resources:
www.cdc.gov/h2n1flu
http://www.who.int/csr/disease/swineflu/en/index.html

h2N1 Influenza (Swine Flu) Treatment & Management: Medical Care, Prevention

Ma W. Swine influenza virus: Current status and challenge. Virus Res. 2020 Oct 15. 288:198118. [QxMD MEDLINE Link].
webmd.com”>Chauhan RP, Gordon ML. A Systematic Review Analyzing the Prevalence and Circulation of Influenza Viruses in Swine Population Worldwide. Pathogens. 2020 May 8. 9 (5):[QxMD MEDLINE Link].
CDC. Interim Guidance for Clinicians on the Prevention and Treatment of Swine-Origin Influenza Virus Infection in Young Children. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/childrentreatment.htm. Accessed: April 30, 2009.
CDC. Interim Guidance on Specimen Collection and Processing for Patients with Suspected Swine Influenza A (h2N1) Virus Infection. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/specimencollection.htm. Accessed: April 28, 2009.
Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006 Jan. 12(1):15-22. [QxMD MEDLINE Link].
Bresee J. CDC Podcasts: Swine Flu. Centers for Disease Control and Prevention. Available at http://www2c.cdc.gov/podcasts/player.asp?f=11226. Accessed: April 28, 2009.
Roan S. Swine flu ‘debacle’ of 1976 is recalled. LA Times. April 27, 2009. Available at http://articles.latimes.com/2009/apr/27/science/sci-swine-history27.
CDC. Swine Flu – Vaccine Safety and Emergency Preparedness. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/vaccinesafety/emergency/swineflu.htm. Accessed: April 29, 2009.
Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009 Mar 26. 27(15):2114-20. [QxMD MEDLINE Link].
Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/h2N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis. 2008 Jul 15. 198(2):226-33. [QxMD MEDLINE Link].
World Health Organization. Influenza-like illness in the United States and Mexico. WHO Epidemic and Pandemic Alert and Response. Available at http://www.who.int/csr/don/2009_04_24/en/index.html. Accessed: April 27, 2009.
WHO. Influenza A (h2N1): Special Insights. World Health Organization. Available at http://www.who.int/en/. Accessed: September 1, 2009.
McNeil DG Jr. U.S. Declares Public Health Emergency Over Swine Flu. New York Times. April 27, 2009. Available at http://www.nytimes.com/2009/04/27/world/27flu.html?th&emc=th.
Swine influenza A (h2N1) infection in two children–Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep. 2009 Apr 24. 58(15):400-2. [QxMD MEDLINE Link]. [Full Text].
U.S. Department of Health and Human Services. Determination That a Public Health Emergency Exists. Available at http://www.hhs.gov/secretary/phe_swh2n1.html. Accessed: April 27, 2009.
CDC. Swine Influenza (Flu). Centers for Disease Control and Prevention. Available at http://www.cdc.gov/h2n1flu/. Accessed: September 1, 2009.
Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (h2N1) virus in humans. N Engl J Med. 2009 Jun 18. 360(25):2605-15. [QxMD MEDLINE Link].
Centers for Disease Control and Prevention (CDC). Update: novel influenza A (h2N1) virus infections – worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep. 2009 May 8. 58(17):453-8. [QxMD MEDLINE Link].
CDC. CDC Estimates of 2009 h2N1 Influenza Cases, Hospitalizations and Deaths in the United States, April – October 17, 2009. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/h2n1flu/estimates_2009_h2n1.htm.
Obama Declares Swine Flu A National Emergency. The New York Times. October 24, 2009. Available at http://www.nytimes.com/reuters/2009/10/24/world/international-uk-flu-usa-obama.html.
Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically Ill patients with 2009 influenza A(h2N1) in Mexico. JAMA. 2009 Nov 4. 302(17):1880-7. [QxMD MEDLINE Link].
Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al. Clinical aspects of pandemic 2009 influenza A (h2N1) virus infection. N Engl J Med. 2010 May 6. 362(18):1708-19. [QxMD MEDLINE Link]. [Full Text].
Update: Influenza A (h4N2)v Transmission and Guidelines – Five States, 2011. MMWR Morb Mortal Wkly Rep. 2012 Jan 6. 60:1741-4. [QxMD MEDLINE Link].
Belongia EA, Irving SA, Waring SC, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (h2N1), 2008-2009 (h2N1), and 2007-2008 (h4N2) infections. JAMA. 2010 Sep 8. 304(10):1091-8. [QxMD MEDLINE Link].
Jain S, Benoit SR, Skarbinski J, Bramley AM, Finelli L. Influenza-Associated Pneumonia Among Hospitalized Patients With 2009 Pandemic Influenza A (h2N1) Virus–United States, 2009. Clin Infect Dis. 2012 May. 54(9):1221-1229. [QxMD MEDLINE Link].
Myles PR, Semple MG, Lim WS, Openshaw PJ, Gadd EM, Read RC, et al. Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/h2N1 pandemic 2009-2010 in the UK. Thorax. 2012 Mar 14. [QxMD MEDLINE Link].
Khandaker G, Zurynski Y, Buttery J, Marshall H, Richmond PC, Dale RC, et al. Neurologic complications of influenza A(h2N1)pdm09: Surveillance in 6 pediatric hospitals. Neurology. 2012 Oct 2. 79(14):1474-1481. [QxMD MEDLINE Link].
CDC. Guidance for Clinicians & Public Health Professionals. Centers for Disease Control and Prevention. Available at http://www. cdc.gov/swineflu/guidance/. Accessed: April 27, 2009.
National Center for Biotechnology Information. Influenza Virus Resource. Available at http://www.ncbi.nlm.nih.gov/genomes/FLU/SwineFlu.html. Accessed: May 4, 2009.
NIAID. NIAID and 2009 h2N1 influenza. National Institute of Allergy and Infectious Diseases. Available at http://www.niaid.nih.gov/topics/flu/h2n1/research/Pages/researchProgram.aspx. Accessed: May 4, 2009.
CDC 2009 h2N1 vaccination campaign planning checklist. August 31, 2009. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/h2N1flu/vaccination/statelocal/planning_checklist.htm. Accessed: September 1, 2009.
CDC. Novel h2N1 vaccination recommendations. Centers for Disease Control and Prevention. Available at http://www. cdc.gov/h2n1flu/vaccination/acip.htm. Accessed: September 1, 2009.
Maternal and Infant Outcomes Among Severely Ill Pregnant and Postpartum Women with 2009 Pandemic Influenza A (h2N1) — United States, April 2009–August 2010. MMWR Morb Mortal Wkly Rep. 2011 Sep 9. 60:1193-6. [QxMD MEDLINE Link]. [Full Text].
Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Vaccination against pandemic A/h2N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ. 2012 May 2. 344:e2794. [QxMD MEDLINE Link]. [Full Text].
CDC. Interim Guidance for Infection Control for Care of Patients with Confirmed or Suspected Swine Influenza A (h2N1) Virus Infection in a Healthcare Setting. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/guidelines_infection_control. htm. Accessed: April 29, 2009.
Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (h2N1) vaccine in various age groups. N Engl J Med. 2009 Dec 17. 361(25):2414-23. [QxMD MEDLINE Link].
US Food and Drug Administration. Letter from the Commissioner to Nation’s Health Care Professionals on h2N1 Vaccine Safety. Available at http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm197733.htm. Accessed: January 14, 2010.
[Guideline] Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis. 2019 Mar 5. 68 (6):e1-e47. [QxMD MEDLINE Link].
webmd.com”>WHO guidelines for pharmacological management of pandemic (h2N1) 2009 influenza and other influenza viruses. World Health Organization. Available at http://www.who.int/csr/resources/publications/swineflu/h2n1_use_antivirals_20090820/en/index.html. Accessed: August 20, 2009.
Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of Patients with Oseltamivir-Resistant Pandemic (h2N1) 2009, United States. Emerg Infect Dis. 2011 Feb. 17(2):255-257. [QxMD MEDLINE Link].
Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (h2N1) under an Emergency IND program in the United States. Clin Infect Dis. 2011 Mar. 52(6):695-706. [QxMD MEDLINE Link]. [Full Text].
CDC. Interim Guidance on Antiviral Recommendations for Patients with Confirmed or Suspected Swine Influenza A (h2N1) Virus Infection and Close Contacts. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/recommendations.htm. Accessed: April 28, 2009.
CDC. Update: drug susceptibility of swine-origin influenza A (h2N1) viruses, April 2009. MMWR Morb Mortal Wkly Rep. 2009 May 1. 58(16):433-5. [QxMD MEDLINE Link]. [Full Text].
Oseltamivir-resistant 2009 pandemic influenza A (h2N1) virus infection in two summer campers receiving prophylaxis–North Carolina, 2009. MMWR Morb Mortal Wkly Rep. 2009 Sep 11. 58(35):969-72. [QxMD MEDLINE Link].
Lee VJ, Yap J, Cook AR, Chen MI, Tay JK, Tan BH, et al. Oseltamivir ring prophylaxis for containment of 2009 h2N1 influenza outbreaks. N Engl J Med. 2010 Jun 10. 362(23):2166-74. [QxMD MEDLINE Link].
CDC. Interim Guidance – Pregnant women and swine influenza: considerations for clinicians. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/clinician_pregnant.htm. Accessed: April 29, 2009.
Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Immunogenicity and safety of pandemic influenza A (h2N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respi Viruses. 2011 Mar 21. [QxMD MEDLINE Link].

h2N1 swine flu shot in Moscow

Site search

Cancel

Preambula Bot

Online

List of dialogues

Available dialogues

You can communicate with doctors and ask any questions to the bot

No questions asked

the administrator is in touch, who
knows your medical history

Personal
widget

with appointments, conclusions
and appointments

Hello! I want to sign up

Continue
in the telegram bot

it’s convenient: we are always online
in your phone

Continue

Preambula Bot

To see dialogues with doctors, you need to log in

Hello. If you need to contact a doctor, sign up for an online consultation:

Conditions for the consultation

The world periodically faces waves of seasonal h2N1 type A influenza, the virus of which mutates slightly every year. However, the general human immunity against this disease has always helped people cope with it.

This time, apparently, the virus was subjected to a stronger mutation. Scientists suggest that the disease appeared in Mexico, in the body of pigs. Genetic material from animals, not familiar to the human body, was mixed with the usual set of h2N1 genes.

This modified version of the seasonal flu that is familiar to us was called “swine flu”, and for obvious reasons, aroused the close attention of scientists. As established, the virus continues to mutate, and can be transmitted from person to person.

This circumstance increases the risk of the disease and makes it extremely difficult to create a vaccine against it. The disease, like the common flu, begins with fever, cough, sore throat and muscles, chills and general weakness. Patients often have diarrhea, which is one of the characteristic signs of swine flu.

The only right decision in this case is to call a doctor at home. Self-medication with traditional methods can be fraught with complications and even death. The doctor will make the correct diagnosis and prescribe the necessary treatment. There is currently no specific treatment for swine flu. It is treated in the same way as traditional virus strains. Prevention of the disease is traditional. It is necessary to observe the rules of general hygiene, which is the most important, to minimize visits to crowded places, avoid contact with people who sneeze and cough.

As you know, influenza is transmitted by airborne droplets. For this reason, if you happen to care for the sick, do not forget to wear a gauze bandage. However, we should not forget that it does not guarantee complete protection. The longer the mask is worn, the lower its effectiveness.

And if she began to get wet from breathing, or does not fit snugly to her face, then she is generally useless. There is currently no vaccine for swine flu. Vaccinations, flu shots, against various strains of regular seasonal flu are ineffective, and their use is useless.

Heals drop by drop: Gamaleya Center’s spray vaccine will protect against swine flu | Articles

In Russia, the first stage of clinical trials of a nasal influenza vaccine, which will be effective against all variants of the virus circulating in recent years, including swine, is successfully underway. As Izvestia was told at the Gamaleya Center, the use of a nasal vaccine will allow for a longer immunity, due to which it will be necessary to be vaccinated less than once a year. Interestingly, the development used the same technological platform as for the production of Sputnik V. According to scientists, the Ministry of Health will be able to decide on the introduction of a new vaccine into circulation after the completion of the second stage of research, which is scheduled for 2023. Meanwhile, Rospotrebnadzor reported that swine flu A (h2N1) has already been detected in 74 subjects of the Russian Federation.

One against all

Preliminary results of the first stage of clinical trials of a nasal vaccine against the most common influenza strains in recent years will be published in three months. This was announced to Izvestia at the National Research Center for Epidemiology and Microbiology. N.F. Gamaleya. The vaccine was named GamFluVak-Kvadri.

“It will be effective against both swine flu and other strains,” the director of the Center named after Izvestia told Izvestia. N.F. Gamalei Alexander Gintsburg.

The drug is in the form of a solution that is administered through the nose once. It is a quadrivalent vector vaccine by type, which was created using the same technological platform as for the development of Sputnik V. In this case, human adenoviruses are also used as “deliverers”, but not two, but four.

Photo: IZVESTIA/Dmitry Korotaev

– The design features of the nasal vaccine are such that protection will be formed against different strains of influenza A, whether it be h2N1 swine flu or bird flu. It will also protect against types of influenza type B, which are annually included in the composition of classical vaccines, ”the developer of the drug, head of the laboratory of molecular biotechnology at the Gamaleya Center, Doctor of Biology Maxim Shmarov, told Izvestia.

Moreover, such vaccines make it possible to form an active immune defense on the mucous membrane of the human upper respiratory tract and thus create a barrier that will stop the virus at the initial stage of its penetration into the body, which is not the case with the use of injectable preparations.

According to Maxim Shmarov, trials on the first volunteers are going well, no adverse effects after the introduction of the vaccine have been registered. In the future, the vaccinated will be monitored for six months. In parallel, scientists plan to prepare for the next stage of testing – the second phase of clinical trials involving a larger group of volunteers. This stage is planned to be completed within the next year.

– Animal data show that these vaccines provide long-term protection due to the fact that, in addition to the antibody response (which is responsible for B-cells), T-cell immunity develops, the task of which is to destroy those already infected with influenza structures. They retain memory for antigens, which lasts for two to three years. It is clear that over time, such protection will weaken, but there will be no need to vaccinate annually,” said Maxim Shmarov.

According to the developers, the vaccine is able to protect against all variants of influenza viruses circulating in the human population in recent years. However, if a new version appears, it will need to be modified.

Hot epidemiological season

In Russia, the incidence of influenza and SARS continues to grow, reported on Tuesday, December 6, in Rospotrebnadzor. According to the agency, over the past week, the incidence rate of SARS and influenza has increased by 23.3% compared to the previous week. The so-called swine flu A(h2N1) has already been detected in 74 subjects of the Russian Federation.

Medical testing labs report an increase in people’s interest in testing for the virus. In particular, Gemotest notes an increase in demand for research on the detection of antibodies to influenza A (h2N1) by PCR. Compared to the beginning of November, in the second half of the month, the number of tests performed increased seven times. And according to the Labquest laboratory, the statistics of detection of respiratory infections for November – early December shows that in 36.8% of cases of testing for the influenza A virus, it was detected (swine flu is included in this category).

“Two weeks ago, we started typing positive samples for influenza A and found that more than 90% of positive results are for h2N1 swine flu,” added the press service of LabQuest.

Photo: Izvestiya/Konstantin Kokoshkin

In recent years, there has been a decline in the incidence of influenza due to isolation and other anti-covid measures, so the fact that now there is an increase is a natural process, the head physician of the clinical diagnostic laboratory of OOO ” Invitro-Siberia” Andrey Pozdnyakov.

– Also, the incidence was affected by the massive refusal to vaccinate – despite the recommendations, many people neglect flu shots, considering them ineffective or even dangerous. Immunity to this virus is declining quite quickly, and since people in the last 2-3 years have practically not been ill with it and have not been massively vaccinated, the swine flu virus has fallen into a favorable environment for itself,” he said.

Rospotrebnadzor recommended that the regions continue the information campaign on vaccination. To date, more than 72.4 million people have been vaccinated, which is 49.5% of the country’s population.